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There has long been evidence that hepatitis C can lead to persis-
tent infection in a high proportion of infected individuals, and can
progress to chronic liver disease, cirrhosis and hepatocellular car-
cinoma (HCC). The transition from acute to chronic hepatitis C is
usually sub-clinical. Accurate studies of the time course for clear-
ance of acute hepatitis C are difﬁcult to carry out because of the
silent onset of the acute disease. The likelihood of spontaneous
HCV resolution is associated with several genetic factors, includ-
ing IL28B inheritance and the DQB1⁄0301 allele of the major
histocompatibility complex class II. Most data suggest that reso-
lution in the acute phase without progression to chronic disease
is not accompanied by signiﬁcant disease, but minor histological
lesions have been observed in anti-HCV positive, HCV RNA nega-
tive individuals. The risk of reinfection remains a possibility after
clearance of acute hepatitis C. High rates of sexually-transmitted
infection are being reported in HIV positive men who have sex
with men (MSM). Chronic infection with HCV is the leading cause
of end-stage liver disease, hepatocellular carcinoma (HCC) and
liver related death in the Western world. The natural history of
the chronic disease remains incompletely deﬁned. It is generally
a slowly progressive disease characterized by persistent hepatic
inﬂammation, leading to the development of cirrhosis in
approximately 10–20% of patients over 20–30 years of HCV
infection. However, the published data indicate varying
progression rates to cirrhosis. Overall, once cirrhosis hasJournal of Hepatology 20
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risk of hepatic decompensation. Following an episode of decom-
pensation the risk of death in the following year is between 15%
and 20%. The high number of chronically infected individuals, the
burden of disease, and the absence of a vaccine indicates that
treatment will form part of the disease control but the impact,
effectiveness and outcomes of treatment in various groups
remain uncertain. Several studies and meta-analysis have con-
cluded that eradication of HCV with antiviral therapy reduces
the risk of HCC in patients with chronic hepatitis C, independent
of ﬁbrosis stage, but the risk is not eliminated.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Non-A non-B hepatitis was formerly identiﬁed as a putative
viral hepatitis occurring after transfusion of blood products or
intravenous drug use. There was evidence that non-A non-B
hepatitis could lead to persistent infection in a high proportion
of infected individuals, and could progress to chronic liver dis-
ease, cirrhosis and hepatocellular carcinoma (HCC). HCV was
discovered to be the major cause of non-A non-B hepatitis in
1989, and is now known to be a leading cause of chronic
liver disease in both industrialised and developing countries.
Within Europe the sero-prevalence increases with age
with a peak prevalence occurring in 55–64 year old patients;
Southern and Eastern Europeans have the highest peak
prevalence [1].
The high number of chronically infected individuals, the bur-
den of disease and the absence of a vaccine indicates that treat-
ment will form part of the control of the disease. However the
majority of those with persistent infection are unaware of the
infection, and screening programs to identify patients will be
required to prevent silent progression of the disease [1,2]. The
high prevalence and incidence of hepatitis C necessitates that
treatment to prevent disease forms part of the perceived strategy
to limit control of the disease, but the impact, effectiveness and
outcomes of treatment in various groups remains uncertain.
The overall impact of treatment for patients with mild or
advanced disease may differ, and the effect of widespread
treatment on the future burden of disease will need ongoing
evaluation, particularly to reduce the prevalence of infection
and disease.14 vol. 61 j S58–S68
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Acute hepatitis C
• Up to 4 million people are newly infected with HCV 
annually
• The acute illness is clinically mild and is typically 
unrecognised and undiagnosed
• Between 18-34% of infected individuals spontaneously 
clear HCV
• Acute resolution of HCV is not associated with any long- 
term sequelae
• Treatment is indicated in patients who are deemed to 
develop chronic hepatitis
Chronic hepatitis C
• Is the leading cause of end-stage liver disease, 
hepatocellular carcinoma and liver related deaths in the 
Western world
• The effects of chronic hepatitis C extend beyond liver 
related morbidity and impact on the overall quality of life
• Fibrosis progression rates are extremely variable and 
are influenced by host, viral and environmental factors
• Achievement of a sustained virologic response (SVR) 
is associated with a reduction in portal hypertension, 
hepatic decompensation, hepatocellular carcinoma and 
liver related mortality
• Following liver transplantation fibrosis rates are 
accelerated with graft cirrhosis rates of 30% at 5 yearsAcute hepatitis C
Populations at risk of acute hepatitis C are patients who received
blood transfusions, blood products or anti D immunoglobulin in
pregnancy prior to 1990, before routine screening of blood
products for HCV, intravenous drug users and intra nasal cocaine
users, patients with tattoos or body piercings, heath care workers,
dialysis patients, and those partaking in high risk sexual
activities. Since the introduction of routine screening of blood
products and sterile injection needles the principal cohorts of
newly infected patients has changed. The majority of patients
presenting as new cases in developed countries now are people
who inject drugs and men who have sex with men [3]. Estimates
of the annual incidence indicate that three to four million persons
are newly infected each year and 350,000 people die annually
from HCV related causes [4]. The acute illness is clinically mild
and typically unrecognised and thus, it is only infrequently diag-
nosed, particularly in those who progress to chronic hepatitis.
After six months of persistence of HCV RNA within the blood
the infection is deﬁned as being chronic. The transition from
acute to chronic hepatitis C is usually sub-clinical. The initial
features of the acute illness are non-speciﬁc ﬂu-like symptoms.Journal of Hepatology 201They are not diagnostic of HCV in particular, as they are common
to many acute viral infections. More speciﬁc symptoms of viral
hepatitis can be encountered in a minority of individuals: jaun-
dice, dark urine, anorexia, aversion to smoking among smokers
and abdominal discomfort may occur. Physical ﬁndings are usu-
ally minimal, apart from jaundice in a third of patients. Chronic
hepatitis is the most common outcome, usually characterized
by raised serum aminotransferases and may lead to ﬁbrosis and
cirrhosis in the liver. Thus chronicity is the major complication
of acute hepatitis C.
Accurate studies of the time course for clearance of acute
hepatitis C are difﬁcult to carry out because of the silent onset
of the acute disease. Studies to determine the rate of persistence
are few and may be biased by the mode of ascertainment. They
frequently involve the prospective study of symptomatic individ-
uals, who are more likely to clear the virus [5,6]. Asymptomatic
individuals are more difﬁcult to identify for obvious reasons.
In the studies that are available, it is frequently stated that
15–40% of individuals resolve their acute disease and do not pro-
gress to chronic hepatitis, based largely on retrospective studies
of post-transfusion hepatitis. This range points to a degree of
uncertainty. Factors such as the immune response, determined
by host genetics, gender, mode of acquisition, the severity of
the acute illness, presentation with jaundice, a poorly deﬁned
weak immune response, immunosuppression with for example
corticosteroid treatment, which can affect clearance of HCV,
HIV co-infection, are all determinants of the acute response. This
means that the time course of clearance is difﬁcult to establish
with certainty. The likelihood of spontaneous HCV resolution is
associated with several genetic factors, including IL28b inheri-
tance and the DQB1⁄0301 allele of the major histocompatibility
complex class II2 [5,7,8].
Grebely et al. showed among 632 individuals with acute hep-
atitis C that spontaneous clearance occurred in 173 of 632, and
at 1 year after infection, 25% had cleared HCV [6]. Among those
with clearance, themedian time to clearancewas 16.5 weekswith
34%, 67%, and 83% demonstrating clearance at 3, 6, and
12 months. Female sex was associated with clearance. Although
there have been few opportunities for longitudinal studies of
acute hepatitis, those which are available show considerable var-
iance: a review of 675 individuals showed that clearance of infec-
tion ranged from 0% to 80% with a weighted mean of 26% [9].
Females were more likely to clear than males (40% vs. 22%) and
patients with identiﬁed clinical infectionwere more likely to clear
than those that were identiﬁed through serological incidence
studies (revealed by seroconversion from negative to positive
anti-HCV) (31% vs. 18%). Wang et al. indicated that 18% of 67 indi-
viduals had spontaneously cleared hepatitis C after 6 months of
follow up [9]. Yeung et al. showed that 28% of 157 children cleared
HCV [10]. Importantly Cox et al. studied 179 anti-HCV negative
injection drug users [11]. After prospective evaluation 62 (34%)
had seroconverted to anti-HCV. HCV RNA was measured by Cobas
Amplicor test (RT PCR) and by transcription mediated ampliﬁca-
tion (TMA, Chiron). Detectable RNA typically preceded detection
of the antibody by 5–6 weeks and HCV RNA detection typically
preceded elevation of ALT [11]. In a subset of the cohort, 20
patients cleared viraemia. Viral recovery was deﬁned as the pres-
ence of anti-HCV antibody with HCV RNA undetectable by the
COBAS assay obtained during at least 2 consecutive visits more
than 300 days after initial detection of viraemia. Their paper illus-
trates several patterns of viraemia during acute hepatitis C. No4 vol. 61 j S58–S68 S59
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subjects had jaundice. It is however noteworthy that although ALT
increases from baseline were noted for several individuals, the
early increases in ALT concentrations (from baseline) still fell
within the normal range. In subjects with viral persistence, a sta-
ble level of HCV RNAwas noted within 60 days of initial detection
of viraemia, but in others, stable viraemia was not apparent until
more than 1 year later. In subjects with long-term viral clearance
HCV RNA became undetectable as early as 94 days but as late as
620 days after initial viraemia. Some patients showed patterns
of viraemia in which periods of detectable viraemia were sepa-
rated by intervals in which HCV RNA could not be detected (viral
sequence data excluded reinfection, but re-infection could be
detected in one subject with persistence). These data point to a
spectrum of viral load declines and variable rates of clearance of
acute hepatitis C. A similar proportion of patients with genotype
4 may clear the acute infection [12].
In persistently infected persons neutralizing antibody
responses have been shown to be broader in persons who con-
trolled viraemia and were detected earlier [13]. A strong IFN-
gamma-mediated antiviral NK cell response was associated with
a self-limited course of acute hepatitis C in HIV positive patients
[14]. IFNL4 ss469415590 polymorphism has been strongly asso-
ciated with response to IFN therapy in HCV-positive HIV-negative
individual’s but not in HIV-positive patients.
Most data suggests that resolution in the acute phase without
progression to chronic disease is not accompanied by signiﬁcant
disease, but minor histological lesions have been observed in
anti-HCV positive, HCV RNA negative individuals. Haydon et al.
found that ten of 12 patients who were RT-PCR negative for
HCV RNA in serum were RT-PCR positive in liver; however, this
group had signiﬁcantly lower intrahepatic HCV concentrations
and serum ALT levels. Some had cirrhosis. The signiﬁcance of
these lesions and their relationship to acute resolved hepatitis
C remains doubtful [15]. The impact of ongoing alcohol use in
anti-HCV positive, HCV RNA negative individuals remains impor-
tant: McMahon et al. compared survival data from subjects that
were chronically infected with those who recovered from HCV
infection, stratiﬁed by alcohol use. No difference was discerned
among heavy alcohol users in the incidence of liver related deaths
or end stage liver disease in those with chronic HCV, compared
with those recovered from HCV infection [16].The effects of treatment of acute hepatitis C
Treatment is indicated in patients who are deemed to develop
chronic hepatitis. This time frame is somewhat arbitrary because
the transition between acute and chronic hepatitis C is not clearly
delineated as some patients remain viraemic for longer than six
months during the acute phase. Although it is important to recog-
nise the disease in the acute phase, it is frequently unrecognised.
Intervention with IFN, or IFN and RBV for hepatitis C, to reduce
the risk of chronic hepatitis, is required and indeed is frequently
applied in patients with acute hepatitis C before six months of
viraemia have ensued. Pegylated IFN (PEG IFN) with or without
ribavirin (RBV) for 24 weeks or longer induces high rates of viral
clearance. The optimal treatment regimen and guidelines for the
appropriate time to treat have not yet been standardized. Symp-
tomatic hepatitis C is less likely to progress to chronic hepatitis C.
Response rates are lower in patients treated later than 20 weeks
post infection. If the HCV RNA remains positive after 12 weeks ofS60 Journal of Hepatology 201observation it is reasonable to consider that therapy should be
initiated. There may be a beneﬁt in treating all viraemic patients
who have not spontaneously cleared the virus by 12 weeks after
onset because of the risk of loss to follow-up in at risk patients.
Newer antiviral agents may alter this thinking.
A pilot study of combination therapy with telaprevir, PEG IFN,
and RBV in acute genotype 1 HCV infection in HIV-infected men
has been completed. In the telaprevir group, 84% (16/19) of men
achieved SVR 12% vs. 63% in a prior comparator group. Most
patients (81%) who achieved SVR in the telaprevir group received
12 weeks of treatment [17].Reinfection after clearance of acute hepatitis C
The risk of reinfection remains a possibility after clearance of
acute hepatitis C. High rates of sexually-transmitted infection
are being reported in HIV positive men who have sex with men
(MSM). Re-screening for active hepatitis C will be necessary in
HIV positive MSM after a single antibody test or following spon-
taneous or treatment-induced resolution because of the substan-
tial incidence of hepatitis C in this group [18]. The Australian Trial
in Acute Hepatitis C (ATAHC) deﬁned re-infection and super-
infection as detection of infection with an HCV strain distinct
from the primary strain after spontaneous or treatment-induced
suppression. Among 163 patients, 111 were treated, and 60%
achieved SVR. However, recurrence was observed in 19%: 12 with
relapse and ﬁve with reinfection (4.7 cases per 100 person-years).
Reinfection occurred more frequently in those with ongoing
injecting drug use. Reinfection in intravenous drug users, has
been described, based on Sanger sequencing. However, interest-
ingly pyrosequencing has suggested that previously undetected
variants present in the post-treatment sample could represent
the emerging dominance of pre-existing minority variants rather
than reinfection [19].
Relative prevalence reductions have been predicted with
varying treatment rates and sustained virological response rates
in people with injecting drug use (PWID). The impact on preva-
lence will hopefully be increased with higher rates of treatment
and higher rates of SVR; reinfection rates may however increase
with simpler IFN free treatments, unless behavioural changes
accompany treatment [20]. Prevention models are being
examined. MSM who clear HCV infection remain at high risk of
reinfection [21].Chronic hepatitis C, its outcome and the effect of treatment
Chronic infection with HCV is the leading cause of end-stage liver
disease, hepatocellular carcinoma (HCC) and liver related death in
the Western world. It is generally a slowly progressive disease
characterized by persistent hepatic inﬂammation leading to the
development of cirrhosis in approximately 10–20% of patients
over 20–30 years of HCV infection. However, the published data
are variable with progression rates to cirrhosis quoted from as
low as 2–3% to as high as 51% over 22 years [22,23]. It is not
uncommon for patients to remain undiagnosed with hepatitis C
until they present with the complications of end stage liver dis-
ease. Once cirrhosis is established the disease progression remains
unpredictable: cirrhosis can remain indolent for many years in
some patients whilst progressing in others to hepatocellular4 vol. 61 j S58–S68
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carcinoma, hepatic decompensation and death. Overall once cir-
rhosis has developed there is a 1–5% annual risk of HCC and a
3–6% annual risk of hepatic decompensation. Following an epi-
sode of decompensation the risk of death in the following year
is between 15% and 20%.
The natural history of the disease remains incompletely
deﬁned. Patient cohort studies have included heterogenous pop-
ulations and often have many co-founders, which can impact on
the progression of hepatic ﬁbrosis. The above complexities have
resulted in the majority of published studies being retrospective,
with prospective studies limited due to the difﬁculty identifying
patient cohorts and the long length of follow-up required to reach
meaningful end points. Retrospective data regarding the natural
history of hepatitis C after treatment have several limitations.
First, it is likely to be skewed towards patients whose disease
has resulted in hepatic complications and hence sought medical
input. The timing of the initial infection will be based on patient’s
recall of ﬁrst contact with blood products or intravenous drug
abuse which can often be inaccurate. In retrospective studies, cir-
rhosis rates have been reported to be between 17% and 55%, HCC
rates 1% and 23%, and liver related death 1% and 23% over an
estimated infection period between 20 and 30 years [22,24,25].
Prospective data are available regarding the natural history of
hepatitis C but it are limited by relatively short follow-up periods
and are only available in well-deﬁned patient cohorts. Data
obtained from prospective studies typically show lower complica-
tion rates as these studies are not reliant on patients seekingmed-
ical care to be identiﬁed. One such cohort were women infected
with hepatitis C following administration of anti D immune glob-
ulin during pregnancy. Over a follow-up period of 18–20 years the
incidence of histologically conﬁrmed cirrhosis was reported to be
between 1% and 2% and bridging ﬁbrosis between 2% and 10%
[26]. A further community based study in America identiﬁed
hepatitis C antibodies in over 1500 young intravenous drug
abusers who were followed for a median of 8.8 years [27]. Over
this time period 10% of patients spontaneously cleared the virus,
4.4% developed end stage liver disease and a further 2% were
identiﬁed as having cirrhosis histologically [27].
Recent data have demonstrated that development of hepatic
ﬁbrosis in hepatitis C is multi-factorial and many co-factors have
been identiﬁed which increase an individual’s risk of developing
signiﬁcant ﬁbrosis or cirrhosis. These include age at infection,
male gender, alcohol consumption, obesity, insulin resistance,
type 2 diabetes, co-infection with hepatitis B or HIV, immunosup-
pressive therapy and genetic factors. Regressive variables that
inﬂuence ﬁbrosis rates may change with time and hence disease
progression of hepatitis C is not necessarily linear [28].
Due to the complex array of variables inﬂuencing disease pro-
gression it is thus difﬁcult to deﬁne prognosis at an individual
level and hence, the overall impact of treatment at various stages
and patterns of disease. An understanding of the natural history
of chronic hepatitis C and its long-term consequences is critical
to enable appropriate decisions regarding monitoring vs. the need
and urgency for treatment and the risks and beneﬁts of
treatment.
Although hepatitis C causes persistent hepatitis, the RNA viral
genome does not integrate into the host genome and viral repli-
cation can be curtailed and a virological cure achieved by treat-
ment. Accepted cure is deﬁned as undetectable HCV RNA in
serum at 12–24 weeks following completion of treatment
(sustained virological response, SVR). Our understanding of theJournal of Hepatology 201natural history of the disease is also important in estimating
the beneﬁts of a treatment and the effect of achieving an SVR.
Spontaneous resolution of chronic hepatitis C is relatively
rare, but can occur. Although only a few longitudinal or retro-
spective studies have been reported, the majority of HCV RNA
patients remain positive. Watanabe et al. followed 435 HCV
RNA positive patients for a follow-up period of a mean of
7.2 years [29]. 16/453 patients (3.7%) became RNA negative.
Rates of 0.5% loss per year per person were observed. Amino-
transferase normalization was always preceded by clearance of
serum HCV RNA, which remained negative throughout the
follow-up. HCV RNA was found in the peripheral blood lymphoid
cells, but not in the serum after convalescence. These results
imply that HCV RNA can persist at very low levels in the serum,
peripheral lymphoid cells and brain, and that an intermediate
replicative form of the HCV genome can persist in peripheral
blood mononuclear cells for many years after apparently
complete spontaneous or antiviral therapy-induced resolution
of chronic hepatitis C.
In asymptomatic patients who test positive for anti-HCV
antibodies, small quantities of HCV RNA commonly persist, even
in patients who test negative for HCV RNA in serum by commer-
cial tests. These viral genomes may however be defective. More-
over, it is known that hepatitis C can persist without apparent
liver disease or raised serum ALT. Low-grade hepatitis, and even
low-grade ﬁbrosis can occur in those patients with HCV and ‘‘nor-
mal serum aminotransferases’’ (which are actually higher when
compared to a cohort of healthy individuals) but ﬁbrosis progres-
sion may be less rapid in females with low or normal ALT [30].
Moreover, in HCV patients with ‘‘a normal ALT’’ who received
antiviral therapy, further decline in ALT is observed in virological
responders.Fibrosis progression in HCV
Chronic hepatitis C infection causes cirrhosis in approximately
16% of patients over 20 years [28]. However, ﬁbrosis progression
rates are extremely variable and can be inﬂuenced by host, viral
and environmental factors. The rates of progression are not linear
and may vary between ﬁbrosis stages and accelerate with dura-
tion of infection or aging [31,32]. In patients who have had hep-
atitis for 30 years cirrhosis rates are estimated at 41%, almost 3
times higher than the rates predicted at 20 years duration [28].
Serial biopsies in patients with hepatitis C have shown annual
rates of ﬁbrosis progression to be between 0.1 and 0.2 stages per
year [33,34]. Several factors have been identiﬁed, which increase
an individual’s risk of ﬁbrosis progression. These factors include
age, male gender, alcohol consumption of more than 50 g/day,
obesity, insulin resistance, type 2 diabetes, co-infection with hep-
atitis B or HIV, immunosuppressive therapy, and host genetic fac-
tors. The rates of ﬁbrosis progression increase signiﬁcantly with
age and data suggest that progression rates can be up to 300 fold
higher in patients affected in their 7th decade compared to those
infected in their 3rd decade of life. Male gender increases ﬁbrosis
rates up to ten fold, independent of age [35] and hepatic steatosis
is associated with more severe inﬂammatory activity, ﬁbrosis
progression and a higher incidence of HCC [36,37].
Thein et al. have tried to address risk of ﬁbrosis progression on
an individualized level. They reviewed 111 studies totalling over
33,000 patients and developed models to calculate speciﬁc4 vol. 61 j S58–S68 S61
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progression rates and cirrhosis risk for individual patients to help
further stratify monitoring and surveillance. Once cirrhosis is
established, patients have a 1–5% annual risk of HCC ad a 3–6%
annual risk of hepatic decompensation (variceal haemorrhage,
ascites, encephalopathy). Following an episode of decompensa-
tion the risk of death in the following year is between 15% and
20% [28].
Hepatitis C and HIV can share routes of transmission. Among
patients infected with HIV, the HCV prevalence is 72–92%
amongst IVDU’s, 1–12% in men who have sex with men and
9–27% in heterosexuals. Co-infection with HIV has a negative
impact on the natural history of HCV. Higher levels of circulating
HCV RNA levels occur with a decreased response to IFN treat-
ment, resulting in a more rapid progression of ﬁbrosis and
2–3 times increased risk of cirrhosis and its associated complica-
tions [38,39]. Moreover, with improvement in anti-retroviral
therapies for patients with HIV, liver related morbidity and mor-
tality due to hepatitis C has become a major cause of mortality in
the HIV-HCV co-infected patient population.
Hepatitis B and hepatitis C co-infection is also a frequent (and
probably underestimated) occurrence due to shared modes of
transmission and shared geographical areas where both viruses
are endemic. The estimated prevalence of HBV-HCV co-infection
is 5–20% in HBsAg positive patients and 2–10% in HCV positive
patients, but with marked geographical variation [40]. The
interaction between HBV and HCV is largely undeﬁned due to
the large number of virological and host variables making
deﬁnitive conclusions difﬁcult. There are data to support a higher
prevalence of co-infection in patients with cirrhosis, hepatic
decompensation and HCC although a recent meta-analysis did
not conﬁrm these ﬁndings [41,42].Effects of treatment and SVR on ﬁbrosis and inﬂammation
The majority of patients (57–94%) demonstrate marked improve-
ments in their necro-inﬂammation and ﬁbrosis scores following
SVR [43–46]. However, a small minority (1–14%) of patients have
demonstrated ﬁbrosis progression following a sustained virolog-
ical response [44,45,47]. Young age and platelet count at SVR are
predictive of ﬁbrosis regression. SVR was associated with
improvement in activity scores and a mean reduction in the
ﬁbrosis score in patients with SVR and a lower rate of ﬁbrosis
progression in 187/487 patients who achieved SVR than those
who did not attain SVR or in untreated patients [48].
The HALT C study showed that although serum aminotransfer-
ases, HCV RNA and histologic necroinﬂammatory scores all
decreased signiﬁcantly with maintenance of IFN treatment, there
was no signiﬁcant difference between the groups in the rate of
any primary outcome. The percentage of patients with at least
one serious adverse event was 38.6% in the treatment group and
31.8% in the control group. Long-term therapy with PEG-IFN did
not reduce the rate of disease progression in patients with chronic
hepatitis C and advanced ﬁbrosis, with or without cirrhosis, who
did not have a response to initial treatmentwith PEG-IFN and RBV.
Most of the studies on the effect of treatment on ﬁbrosis have
been limited by lack of long-term follow up after treatment vs.
untreated patients. Ongoing co-factors such as alcohol and meta-
bolic syndrome are likely to play a signiﬁcant role. This highlights
the importance of ongoing follow-up of patients with advanced
ﬁbrosis and attempting to address all hepatic risk factors.S62 Journal of Hepatology 201Achievement of SVR is associated with a reduction in portal
hypertension, hepatic decompensation, and hepatocellular
carcinoma [47,49,50]. Veldt et al. reported the outcomes in con-
secutively treated patients with chronic hepatitis C with histolog-
ically proven advanced ﬁbrosis or cirrhosis. SVR was correlated
with clinical outcomes, including death (liver or non-liver
related), liver failure and hepatocellular carcinoma. Of 479
patients, 29.6% had sustained virologic response. The median
follow-up was 2.1 years. SVR was associated with a statistically
signiﬁcant reduction in the hazard of events, an effect which
was largely attributable to a reduction in liver failure.Effects of treatment on portal hypertension and liver failure in
HCV
Cirrhosis and portal hypertension are major determinants
impairing SVR in IFN treated patients. Thus, disease severity is
a major independent determinant of the rate of SVR in patients
with advanced chronic hepatitis C, but arresting disease severity
is the critical focus of treatment. Portal hypertension results as a
consequence of progressive ﬁbrosis and architectural remodel-
ling of the liver as a response to ongoing inﬂammation. Hepatic
ﬁbrosis creates resistance to sinusoidal blood ﬂow and results
in increased portal venous pressure. Gastric and oesophageal var-
ices develop as a result of the increased portal venous pressure.
Overall gastro-oesophageal varices are present in 50% of patients
with cirrhosis, but their incidence correlates with the severity of
liver disease with a prevalence of 85% in patients with Child-Pugh
C cirrhosis. Bleeding from ruptured oesophageal varices is the
second highest cause of mortality, after HCC, in cirrhotic patients
with hepatitis C [51,52].
In patients with hepatitis C the prevalence of upper gastroin-
testinal varices is approximately 16% with Ishak grade 3 to 4
ﬁbrosis and 39% in patients with biopsy proven cirrhosis. In a
recent study of 1016 patients only 12 (0.01%) had large varices
(impingement of >50% of lumen). Furthermore, although many
subjects with bridging ﬁbrosis had varices, these were generally
small or medium size with no high risk stigmata for bleeding.
The incidence of varices in patients with cirrhosis or advanced
ﬁbrosis is estimated to be 6.5% per year, with a 1% per annum risk
of variceal haemorrhage. In patients with pre-existing varices the
annualized rate of progression was 8.8% [50,53].
Non-cirrhotic patients who have achieved SVR will not
progress to liver failure or portal hypertension and do not need
ongoing endoscopic surveillance. Patients with HCV cirrhosis
who achieve SVR have a reduction in their portal pressure mea-
surements when compared to non-responders [54]. Although
achieving an SVR prevents the development of oesophageal var-
ices in the majority of patients with compensated HCV cirrhosis,
a recent prospective study showed that although the risk of
developing varices post SVR was vastly reduced it was not
eliminated, with a small number of patients developing small
oesophageal varices (2/57) [55].Effects of treatment on the HCC risk in patients with HCV
The incidence of HCC amongst HCV infected patients is between
1% and 3% at 30 years [56]. Once cirrhosis is established, de novo
HCC develops at a rate between 1% and 4% per annum, with rates4 vol. 61 j S58–S68
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highest in patients contracting hepatitis C from contaminated
blood products [56,57]. Host factors, which increase an individ-
ual’s risk of developing HCC, are similar to those factors described
to increase progression rates to cirrhosis, and include HIV, HBV,
alcohol and diabetes [57]. Once cirrhosis is established male
sex, increasing age and severity of cirrhosis all increase the likely
hood of HCC.
Interesting data regarding the incidence of HCC was obtained
from the HALT C study. The overall rates of HCC development in
cirrhotic patients was 7% over 4.8 years. Importantly, a signiﬁcant
number of patients with Ishak grade 3 or 4 ﬁbrosis also
developed HCC raising questions regarding what deﬁnes need
for screening in cirrhotic and non-cirrhotic patient cohorts.
A key question is the efﬁcacy of IFN plus RBV therapy in
patients with HCV cirrhosis, and the development of HCC. The
cumulative incidence of HCC in 132 HCV-cirrhotic patients
receiving IFN alpha, during a median follow-up period of
37 months, has been reported: HCC developed in fewer patients
with SVR suggesting that achieving SVR may decrease the inci-
dence of HCC in patients with HCV-related cirrhosis [58]. Simi-
larly, Ikeda et al. reported that the hazard ratio of developing
HCC was reduced in IFN treated patients. In 606 patients with
persistent normal ALT with or without HCV-RNA clearance the
risk of HCC was signiﬁcantly lower than that in untreated
patients and those with abnormal aminotransferases [59].
Several studies and meta-analysis have concluded that eradi-
cation of HCV with antiviral therapy reduces the risk of HCC in
patients with chronic hepatitis C, independent of ﬁbrosis stage
[60,61]. It has been suggested that achieving an SVR in patients
with cirrhosis provides a 20% reduction rate in the incidence of
HCC [62].
A recent meta-analysis published in Annals of Internal Medi-
cine included 30 studies comprising of 31,528 patients from 17
different countries [60]. This study reported a 4.6% absolute
reduction in developing HCC following SVR. Furthermore in
patients with advanced liver disease achieving an SVR reduced
the overall risk of developing HCC from 17.8% to 4.2% with a
reduction in incidence from 3.3% per person year to 1.05% (CI
0.7–1.5%) per person year. Prospective data extracted from the
HALT C cohort corroborated the above ﬁndings: following SVR
the incidence of HCC reduced from 8.8% down to 1.1% over
approximately 7 years follow-up.
Whilst achieving an SVR reduces the risk of HCC in patients
with advanced ﬁbrosis or cirrhosis, there is clear evidence that
the risk is not eliminated [61]. Patients with advanced ﬁbrosis
or cirrhosis can develop HCC as long as 8–10 years or beyond
SVR implying that ongoing surveillance for HCC needs to be
continued in patients with advanced ﬁbrosis/cirrhosis [63].
A recent study has tried to risk stratify patients further, by
creating a scoring system based on age, platelets, alpha fetopro-
tein and ﬁbrosis score [64]. Patients were divided into low, med-
ium or high risk dependent on their score. In the low risk group 9
out of 657 patients developed HCC over 9 years equating to a
0.17% risk per annum, an incidence which is well below the
incidence where screening is deemed cost effective. If this score
is validated then it may help identify which patients should be
recommended for long-term HCC surveillance.
In patients without pre-existing signiﬁcant liver disease a SVR
is associated with resolution of risk from liver disease and these
patients can be discharged from ongoing follow-up. In those
patients with advanced ﬁbrosis or established cirrhosis, clearanceJournal of Hepatology 201of the virus lowers an individual’s risk of hepatic complications
but they remain at risk of decompensation and development of
HCC and hence patients with cirrhosis or advanced ﬁbrosis
require ongoing longitudinal follow-up and HCC surveillance.Hepatitis C, liver transplantation and the effects of treatment
The end stage of the natural history of HCV infection is decom-
pensated cirrhosis, HCC and ultimately death. Liver transplanta-
tion (LT) is the only potentially salvage treatment option for
such patients. HCV is currently the leading indication for LT in
the Western world. In those patients who have achieved SVR,
recurrence of hepatitis C in the graft does not occur despite
immunosuppression, and liver transplantation outcomes are
comparable to or even better than those patients transplanted
for other indications. In those who are undergoing treatment
whilst on the LT waiting list and achieve HCV RNA negativity
but have not yet achieved an SVR, HCV recurrence can be reduced
to approximately 30% [65].
In those patients that are HCV RNA positive at the time of
transplantation, HCV reinfection infection of the graft is almost
universal. Disease progression occurs at an accelerated rate in
the post-transplant population when compared to the immuno-
competent patient population. The rapid progression to signiﬁ-
cant ﬁbrosis seen in HCV recipients impacts negatively on
outcome with an overall 20% increased risk of mortality and 30%
increased risk of graft failure when compared to other LT indica-
tions [66]. Whilst HCV recurrence is universal post LT, multiple
factors inﬂuence the severity and rates of ﬁbrosis post-transplant.
The graft is infected at reperfusion from circulating virons.
Detectable HCV propagation and replication is discernable within
hours [67]. Primarily due to profound immunosuppression, HCV
RNA concentrations within the ﬁrst weeks post transplantation
are generally 1 log higher than levels prior to transplantation.
Most patients develop histological evidence of recurrent hepatitis
C between 4 and 12 weeks post-transplant which is often accom-
panied by a further steep rise in circulating viral RNA [67].
Chronic hepatitis is established between 3 and 9 months after
transplantation; the clinical, biochemical and histopathological
ﬁndings are similar to those seen in non-transplant HCV patients.
However the rate of progression to ﬁbrosis is more rapid.
Serial biopsies in patients with recurrent hepatitis C post-
transplant have shown annual rates of ﬁbrosis progression to
be between 0.3 and 0.6 stages/year, (F0–4) compared to rates
between 0.1 and 0.2 in immunocompetent patients [68,69]. The
severity of the histological necro-inﬂammatory activity at
12 months is the best predictor of risk for developing cirrhosis
at 5 years [70,71]. Cirrhosis occurs in up to 30% of those trans-
planted for HCV by 5 years post-transplant, compared to the
average time for the development of cirrhosis in the non-trans-
plant patient being 30 years [69,70]. Once cirrhosis has devel-
oped, the rate of decompensation is also accelerated with
reports of 40% at 1 year and >70% at three years compared to
<5% and <10% respectively in the immunocompetent patients.
A small percentage of patients transplanted for hepatitis C
(2–5%) develop a unique acute severe aggressive form of hepatitis
C recurrence between 1 and 6 months post-transplant. The
syndrome of ﬁbrosing cholestatic hepatitis is characterized by
elevated bilirubin (>6 mg/dl) and a raised alkaline phosphatase
level in the absence of biliary obstruction. Histologically there4 vol. 61 j S58–S68 S63
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is severe hepatocyte ballooning, intrahepatic cholestasis and duc-
tular proliferation in the absence of signiﬁcant lobular inﬂamma-
tion or lymphoid aggregates. HCV RNA concentrations are
typically extremely high and although the pathogenesis is poorly
understood it is thought to be due to a direct cytopathic effect
following massive hepatocyte repopulation with HCV. Despite
occasional case reports of successful outcomes with AVT, the
majority of cases rapidly progress to graft failure and death
within the ﬁrst 12 months following liver transplantation [72].
Patient and graft survival in HCV positive recipients is there-
fore not surprisingly reduced when compared to those patients
transplanted for other indications [73]. In 2002 a multicentre
European study reported 7 year graft and patient survival to be
51% and 55% respectively in HCV-positive recipients compared
to 67% and 70% in HCV negative recipients [74]. Reasons for poor
outcomes post-transplantation in patients with HCV are not
restricted to HCV recurrence. Patients transplanted for HCV have
a higher incidence of associated HCC when compared to other
indications. Over the last decade the understanding of factors,
which may impact negatively on patient and graft survival in
HCV recipients, has improved signiﬁcantly. This has resulted in
improved outcomes post LT for HCV patients however they
remain inferior to patients transplanted for other indications.
Following transplantation, immunosuppression therapy nega-
tively impacts on graft ﬁbrosis rates and survival. Immunosup-
pression is one of the only factors to impact on graft survival,
which can be modiﬁed post transplantation, however, the opti-
mal immunosuppressive strategy remains largely undeﬁned
and is still an area of uncertainty due to a lack of good evidence
supporting superiority of individual or combinations of agents
over others [75]. Fibrosis, secondary to hepatitis C recurrence, is
expedited by the use of repeated boluses of corticosteroid ther-
apy, and anti-lymphocyte antibodies used to treat rejection.
Low dose steroids and slow tapering are associated with better
outcomes than high dose maintenance or slow tapering. There
are no data to support superiority of CyA vs. tacrolimus on HCV
recurrence rates, however, tacrolimus is associated generally
with better post-transplant outcomes when compared with
cyclosporin. There may be a beneﬁcial effect on long-term use
of azathioprine in conjunction with tacrolimus, demonstrated in
a randomised single centre controlled study. The mTOR inhibi-
tors, sirolimus, and everolimus have been associated with signif-
icantly less ﬁbrosis progression in animal models when
compared to calcineurin inhibitor (CNI) therapies. Retrospective
non-randomised studies in humans support this ﬁnding however
but good quality studies are lacking.
Achievement of SVR with antiviral therapy signiﬁcantly
improves graft survival in hepatitis C virus mono-infected liver
transplant (LT) patients. The beneﬁt of HCV therapy in HCV-
human immunodeﬁciency virus (HIV) co-infected liver transplant
recipients are less well established. The low SVR rate and serious
adverse event rate in this group highlight the crucial need for bet-
ter tolerated and more efﬁcacious HCV therapies for both mono
infected and HCV-HIV co-infected transplant recipients [76,77].
IFN treatment of recurrent hepatitis C has not consistently
improved histologic disease after virologic response, and carries
a risk of allograft rejection [78]. Telaprevir and boceprevir have
been utilised to treat post-transplant recurrent HCV. Preliminary
reports indicated that higher SVR rates than achieved with
PEG-IFN and RBV. Severe toxicity, particularly anaemia and
sepsis, and drug-drug interactions with the calcineurin inhibitorsS64 Journal of Hepatology 201complicate the use of boceprevir and telaprevir. Discontinuation
rates of up to 40 percent have been encountered.
There is therefore an urgent need to improve graft survival
and patient outcomes in patients transplanted for hepatitis C or
hepatitis and HCC. Unfortunately, IFN is contraindicated in
patients with decompensated cirrhosis, and few patients can be
treated therefore with IFN and RBV or IFN plus a direct acting
antiviral to achieve a pre-transplant SVR. Fortunately, IFN treat-
ment is being displaced by better tolerated and more effective
combination direct antiviral (DAA) therapies. A preliminary
report of the use of pre-transplant sofosbuvir and RBV for up to
48 weeks, to the day of transplant for patients transplanted for
HCV and HCC (within Milan criteria), has resulted in a 64%
post-transplant SVR rate. The duration of undetectable HCV
RNA pre-transplant was the best predictor of response. The
application of more potent regimens including the combination
of sofosbuvir and an NS5a inhibitor, either daclatasvir or ledipas-
vir, or sofosbuvir plus simeprevir is likely to further reduce the
risk of post-transplant recurrence. However, the safety, efﬁcacy
and duration of DAA combinations in patients with decompen-
sated liver disease and high MELD scores has not been estab-
lished. The outcomes after SVR in patients on a transplant
waiting list are not yet known. It is possible that an SVR in
patients may stabilize a proportion of patients. However, the pro-
portion of patients who can be delisted, and the optimal duration
of treatment, regimens and criteria that predict not only SVR but
clinical improvement have yet to be ascertained. Similarly, the
outcomes and safety in patients with decompensated cirrhosis
not on a transplant waiting list are not yet known.
Sofosbuvir and RBV have been used for the treatment of recur-
rent post-transplant hepatitis C (all genotypes). Virological
response rates of 77% after 24 weeks of treatment have been
reported. Recently Kwo et al. reported that 96% of patients with
genotype 1 post-transplant hepatitis C and mild (less than or
equal METAVIR F2 ﬁbrosis) treated with ABT-450/r/ombitasvir,
150 mg/100 mg/25 mg QD; dasabuvir, 250 mg BID RBV plus or
minus RBV have SVR. CNI dosing was manageable over the dura-
tion of study. It is not yet clear how applicable this regimen
would be for cholestatic hepatitis or decompensated cirrhosis.
These landmark treatments, which will be improved with time,
may greatly reduce the risk and complications of post-transplant
HCV. Further follow-up to ensure the durability of response and
effect on post-transplant HCV will be required and more
information on drug-drug interactions are needed. The need for
re-transplantation should be reduced. It is possible that all
post-transplant recurrent hepatitis C will be treated rather than
deferring treatment until the advent of severe disease. The opti-
mal strategy to reduce post-transplant recurrence and the inclu-
sion criteria to avoid decompensation during treatment
pretransplant will be required as a matter of urgency.Effect on extra-hepatic consequences of hepatitis C infection
Chronic infection with hepatitis C is known to cause several extra
hepatic manifestations. Several diseases including sicca
syndrome, lichen planus, type 2 diabetes and non-Hodgkin’s
lymphoma, have been reported. Overall 15–35% of patient with
chronic HCV have circulating cryoglobulins. Of these between
5% and 25% will develop clinical consequences including mixed
essential cryoglobulinemia, systemic vasculitis, peripheral4 vol. 61 j S58–S68
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neuropathy, Raynaud’s phenomenon, and membranoproliferative
glomerulonephritis. The risk of developing a non-Hodgkins B cell
driven lymphoma is increased, likely as a consequence of
long-term B cell stimulation by the HCV. HCV is also recognized
to inﬂuence several metabolic pathways, with patients more
likely to develop insulin resistance, type 2 diabetes and increased
rates of vascular disease [79,80].
Achieving SVR results in the resolution of immune complex
extrahepatic manifestations, reduces the incidence of lymphoma,
decreases the risk of type 2 diabetes and its associated complica-
tions and improves patients overall quality of life [81,82]. Due to
reduction in the complications above, a sustained virological
response is associated with a reduction in all cause mortality of
54%. Antiviral treatment with IFN-a leads to resolution of cryo-
globulinemia and vasculitis symptoms in most patients who
show a response to antiviral treatment [83]. A full analysis of
the methodology of the studies, documenting the outcomes of
these extrahepatic manifestations after resolution of the disease,
is not possible in this review.C
li
nHIV co-infected patients
There are limited data on the effect of achieving SVR on the HCC
risk in patients with HIV. In papers by Berenguer and Limketkai
there were no reports of HCC in 254 co-infected patients who
achieved SVR. In contrast, recent reports conﬁrm data similar to
the non-HIV population with a signiﬁcant proportion of HCC
developing in patients who have achieved SVR, conﬁrming the
need for ongoing tumour surveillance in this group [84].
In addition to improved overall survival, antiretroviral therapy
has reduced long-term liver-related mortality in co-infected
patients. This survival beneﬁt will be further improved by effec-
tive hepatitis C therapies in co-infected patients, whose prognosis
will be further improved. HCC in patients with HIV co-infection is
increasing in incidence and has a poor prognosis with studies
reporting a 10 fold increase in mortality [85,86]. Co-infection
with HCV accounts for 93% of cases of HCC occurring in patients
with HIV.Treatment effect on health-related quality of life
Chronic hepatitis C infection is recognized to negatively impact
on patients’ quality of life both physically, mentally, emotionally
and socially and the effects of hepatitis C extend far beyond liver
related morbidity [87,88]. Several studies suggest that people
with HCV may have a lower quality of life due to depression,
chronic fatigue, ﬁbromyalgia, and anxiety in comparison to the
general population. During IFN treatment quality of life indices
deteriorate largely due to an increase in depression [89].
Bonkovsky and other authors have shown that patients who
had a sustained response to IFN therapy experienced signiﬁcant
improvements in perceived wellness and functional status [90].
However the effect of treatment on these parameters requires
further study in an era of interferon-free therapy.Treatment effect in PWID
Successful treatment will hopefully have a profound effect on the
incidence and prevalence of HCV infection in PWID. IncreasingJournal of Hepatology 201the proportion of injecting drug users hepatitis C treatment,
achieving a sustained virological response (SVR) is likely to have
an impact on transmission, as has been modelled; it is as yet
uncertain whether these models will translate into a reduced rate
of infection [91].Overall beneﬁt on treatment
The overall impact of HCV treatment on survival has relied on
surrogate end points. More systematic reviews have called into
question the methodology of these assessments and their validity
of the ﬁndings. A Cochrane review systematically evaluated the
beneﬁts and harms of PEG IFN plus RBV vs. IFN plus RBV for
patients with chronic hepatitis C. The primary outcomes were
liver-related morbidity, all-cause mortality, serious adverse
events, and adverse events leading to treatment discontinuation,
other adverse events, and quality of life. Twenty seven random-
ised trials with 5938 participants were included. PEG IFN plus
RBV vs. IFN and RBV seemed to signiﬁcantly increase the number
of participants achieving SVR. However, the authors concluded
that there was insufﬁcient evidence of the potential beneﬁts on
the quality of life in patients with achieved sustained virological
response. Further high-quality research is need to impact on the
conﬁdence in the estimate of patient-relevant outcomes. The
authors concluded that SVR is still an unvalidated surrogate out-
come for patient-important outcomes. Innes et al. suggested that
the beneﬁt of SVR should be considered in terms of two patient-
important outcomes: a percent-probability that SVR confers
additional life-years, and the percent-probability that SVR con-
fers additional healthy life-years. The beneﬁt conferred by SVR
was lowest for patients aged 60 years with initially mild ﬁbrosis
and was highest for patients with initially compensated cirrhosis
aged 30 years [92].Cost effectiveness of cure
An analysis of the cost effectiveness is beyond the scope of this
article. Most analyses have concluded that patients treated with
PEG IFN, beneﬁt, with up to 46% of patients experiencing an
SVR in one of the trials. PEG IFN also appears to be relatively cost
effective with cost per QALY estimates remaining generally under
£30,000. Additional studies are needed for newer DAA therapies,
particularly in patients with mild ﬁbrosis. The most cost effective
policy for reducing the prevalence of hepatitis C infection and
hepatitis C related disease is also being debated, and various
models and scenarios are being proposed [91].Conclusions
Cirrhosis is the major determinant of disease due to hepatitis C.
Thus, arresting severe disease and preventing the onset of severe
disease is the critical focus of treatment. The relatively low
impact and effectiveness of IFN and PEG IFN combined with
RBV on disease burden should be altered by the advent of more
efﬁcacious and effective DAA therapies. Surrogate events point
to treatment conferring an advantage and an effect of cure on
the progression of hepatic ﬁbrosis and clinical events, and
probably on some extra-hepatic manifestations of the disease.4 vol. 61 j S58–S68 S65
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IFN free treatments are more likely to be accepted and could have
an impact on the complications of cirrhosis that will be
discernable in a few years. It is to be hoped that not only the risk
of cirrhosis, decompensated cirrhosis but also HCC, will be sub-
stantially diminished. The effects of chronic alcoholism no doubt
also need to be mitigated to reduce the future burden of disease
related to hepatitis C.
However, these disease outcomes will require careful
measurement. It is likely that the ﬁrst effects will be noted by a
reduction in hospital admissions and requirements for liver
transplantation if patients with cirrhosis are identiﬁed and
treated. A ‘‘curative’’ response to therapy offers hope for millions.
Policy makers will however want proof of impact in patients who
have indolent and not life-threatening disease, because of the
magnitude of the infected population and the cost of current
DAA treatments. Further control of disease will also necessitate
safe blood product use, reduced rates of transmission among
PWID education, safe injections in developing countries, and pos-
sible vaccination.Conﬂict of interest
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